Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01140347 · OUTCOME

Cmax of Ramucirumab, Cycle 4

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib · Source last updated 2015-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
µg/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
1 hour following completion of Cycle 4 (14-day cycles) infusion

Analysis population: Participants who received Cycle 4 of Ram and had Cmax results.

Groups in this outcome

Ramucirumab (IMC-1121B) + BSC

Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ramucirumab (IMC-1121B) + BSC140

Reported measurements

Source class 1
Values in µg/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Ramucirumab (IMC-1121B) + BSC189.539.1Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        39.1
        value
        189.5
denoms
  1. counts
    1. group Id
      OG000
      value
      140
    units
    Participants
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
    id
    OG000
    title
    Ramucirumab (IMC-1121B) + BSC
param Type
GEOMETRIC_MEAN
population Description
Participants who received Cycle 4 of Ram and had Cmax results.
reporting Status
POSTED
time Frame
1 hour following completion of Cycle 4 (14-day cycles) infusion
title
Cmax of Ramucirumab, Cycle 4
type
SECONDARY
unit Of Measure
µg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice